IONS ran two "Phase 3"s - one in FCS (for approval in FCS), and the other more general very high trig (which had some FCS patients). The latter was stat sig in a secondary endpoint for pancreatitis, the former had a meaningful 'trend' (but wasn't stat sig).
Given that the trials were tiny, that is pretty impressive.